[
  {
    "ts": "2025-12-23T02:06:56+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress",
    "summary": "Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following recent upgrades. See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-valuation-check-020656338.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5088e505-3c00-3827-a777-7aa579ca7e6a",
      "content": {
        "id": "5088e505-3c00-3827-a777-7aa579ca7e6a",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following recent upgrades. See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This...",
        "pubDate": "2025-12-23T02:06:56Z",
        "displayTime": "2025-12-23T02:06:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-valuation-check-020656338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-valuation-check-020656338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]